Acurx Pharmaceuticals Investor Relations Material

Acurx Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing antibiotic treatments for bacterial infections. The company's research and development efforts are primarily centered on addressing antibiotic resistance, targeting bacterial pathogens that pose a significant threat to public health. Acurx utilizes a novel approach to inhibit bacterial DNA synthesis, working to combat infections that are increasingly resistant to traditional antibiotics. Its pipeline includes various antibiotic candidates aimed at providing new therapeutic options for patients. The company is headquartered in Staten Island, New York, and its shares are listed on the NASDAQ.